Clinical Trial Update: Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) [Phase 3]

View source ↗

Summary

Phase 3 trial update of aprepitant (MK0869) for prevention of chemotherapy-induced nausea and vomiting in cisplatin-treated patients; trial is completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Status: COMPLETED | Results posted: 2011-09-27